329 related articles for article (PubMed ID: 16444991)
21. Feasibility of simultaneous 18F-FDG PET/MRI for the quantitative volumetric and metabolic measurements of abdominal fat tissues using fat segmentation.
Im HJ; Paeng JC; Cheon GJ; Kim EE; Lee JS; Goo JM; Kang KW; Chung JK; Lee DS
Nucl Med Commun; 2016 Jun; 37(6):616-22. PubMed ID: 26836629
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET and CT characterization of adrenal lesions in cancer patients.
Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
[TBL] [Abstract][Full Text] [Related]
23. The value of fat-suppressed T2 or STIR sequences in distinguishing lipoma from well-differentiated liposarcoma.
Galant J; Martí-Bonmatí L; Sáez F; Soler R; Alcalá-Santaella R; Navarro M
Eur Radiol; 2003 Feb; 13(2):337-43. PubMed ID: 12598999
[TBL] [Abstract][Full Text] [Related]
24. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
25. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
[TBL] [Abstract][Full Text] [Related]
26. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
27. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
28. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.
Hickeson M; Yun M; Matthies A; Zhuang H; Adam LE; Lacorte L; Alavi A
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1639-47. PubMed ID: 12458399
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of lipoma from liposarcoma on MRI using texture and shape analysis.
Thornhill RE; Golfam M; Sheikh A; Cron GO; White EA; Werier J; Schweitzer ME; Di Primio G
Acad Radiol; 2014 Sep; 21(9):1185-94. PubMed ID: 25107867
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of hemangioma by positron emission tomography: role in a multimodality approach.
Hatayama K; Watanabe H; Ahmed AR; Yanagawa T; Shinozaki T; Oriuchi N; Aoki J; Takeuchi K; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(1):70-7. PubMed ID: 12544246
[TBL] [Abstract][Full Text] [Related]
31. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
32. Utility of 18F-FDG uptake in various regions of Waldeyer's ring to differentiate benign from malignant lesions in the midline roof of the nasopharynx.
Chen YK; Wang SC; Cheng RH; Yeh CL; Tsui CC; Chia-Hung K
Nucl Med Commun; 2014 Sep; 35(9):922-31. PubMed ID: 24781010
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
[TBL] [Abstract][Full Text] [Related]
35. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
36. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
[TBL] [Abstract][Full Text] [Related]
38. Schwannoma of the extremities: the role of PET in preoperative planning.
Ahmed AR; Watanabe H; Aoki J; Shinozaki T; Takagishi K
Eur J Nucl Med; 2001 Oct; 28(10):1541-51. PubMed ID: 11685498
[TBL] [Abstract][Full Text] [Related]
39. Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum.
Britz-Cunningham SH; Millstine JW; Gerbaudo VH
Clin Nucl Med; 2008 Oct; 33(10):681-7. PubMed ID: 18806567
[TBL] [Abstract][Full Text] [Related]
40. Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx.
Chen YK; Su CT; Chi KH; Cheng RH; Wang SC; Hsu CH
J Nucl Med; 2007 Jan; 48(1):8-14. PubMed ID: 17204693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
